


Correction

Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. *Cancers* 2020, 12, 3837

Jaco A. C. van Bruggen^{1,2,3,4,5,†}, Anne W. J. Martens^{1,2,3,4,5,†} , Sanne H. Tonino^{1,3,4,5} and Arnon P. Kater^{1,3,4,5,*}

- ¹ Department of Hematology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; j.a.vanbruggen@amsterdamumc.nl (J.A.C.v.B.); a.w.martens@amsterdamumc.nl (A.W.J.M.); s.h.tonino@amsterdamumc.nl (S.H.T.)
- ² Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
- ³ Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands
- ⁴ Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, The Netherlands
- ⁵ Lymphoma and Myeloma Center Amsterdam, LYMMCARE, 1105 AZ Amsterdam, The Netherlands
- * Correspondence: a.p.kater@amsterdamumc.nl
- † These authors contributed equally.



Citation: van Bruggen, J.A.C.; Martens, A.W.J.; Tonino, S.H.; Kater, A.P. Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. *Cancers* 2020, 12, 3837. *Cancers* **2021**, 13, 4738. <https://doi.org/10.3390/cancers13194738>

Received: 18 August 2021
Accepted: 19 August 2021
Published: 22 September 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

In the original article [1], reference [46] was not cited correctly in Table 1. The citation has now been inserted in Section 2.1. “Immune Checkpoint Blockade”, Table 1: the original citation “Zinzani et al., 2019” should read “Zinzani et al., 2019 [46]”.

In the original article, reference [84] was not cited correctly in Table 3. The citation has now been inserted in Section 2.3. “Chimeric Antigen Receptor Therapy”, Table 3: the original citation “Fraietta et al., 2016 [78]” should read: “Fraietta et al., 2016 [84]”.

The reference citation numbers from Section 3.2. “T-Cell Skewing”, paragraph two, line three onwards were incorrectly written as a result of four missing references in the reference section. They have been corrected after the references were reinserted with the following numbers: [103], [117], [153] and [192]:

103. Tinhofer, I.; Weiss, L.; Gassner, F.; Rubenzer, G.; Holler, C.; Greil, R. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. *J. Immunother.* **2009**, *32*, 302–309, doi:10.1097/CJI.0b013e318197b5e4.
117. Song, D.G.; Ye, Q.; Carpenito, C.; Poussin, M.; Wang, L.P.; Ji, C.; Fignini, M.; June, C.H.; Coukos, G.; Powell, D.J., Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). *Cancer Res.* **2011**, *71*, 4617–4627, doi:10.1158/0008-5472.CAN-11-0422.
153. Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. *J. Clin. Investig.* **2008**, *118*, 2427–2437, doi:10.1172/JCI35017.
192. Ramsay, A.G.; Evans, R.; Kiaii, S.; Svensson, L.; Hogg, N.; Gribben, J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. *Blood* **2013**, *121*, 2704–2714, doi:10.1182/blood-2012-08-448332.

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

1. van Bruggen, J.A.C.; Martens, A.W.J.; Tonino, S.H.; Kater, A.P. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. *Cancers* **2020**, *12*, 3837. [[CrossRef](#)] [[PubMed](#)]